Home/Pipeline/TR-987

TR-987

Chronic wounds

Phase 2BCompleted

Key Facts

Indication
Chronic wounds
Phase
Phase 2B
Status
Completed
Company

About Tissue Repair

Australian‑based biotech leveraging beta‑glucan immunomodulation to treat wounds and enhance aesthetic recovery.

View full company profile

Therapeutic Areas

Other Chronic wounds Drugs

DrugCompanyPhase
Tuned Stem Cell EVs for Chronic WoundsZenBioPre-clinical